clear that the QP is not just a symbolic role but a legally accountable function with direct responsibility for compliance.

Common Failure Points Observed in Inspections

EMA and member state inspections often highlight QP-related deficiencies, including:

• Batch release performed without complete review of manufacturing and analytical data
• Over-reliance on third parties without sufficient QP oversight
• Failure to ensure supply chain traceability and GMP compliance of active ingredients
• Incomplete documentation of QP certification decisions
• Insufficient involvement of the QP in deviation and CAPA oversight
• Gaps in ensuring import compliance for products manufactured outside the EU

These failures undermine the credibility of the QP role and can trigger regulatory findings or enforcement actions.

Root Causes and Contributing Factors

Root causes behind deficiencies in QP oversight typically include:

• Lack of clear SOPs defining the scope of QP review and decision-making
• Insufficient communication between QP and production/quality teams
• Excessive workload with multiple facilities or high batch volumes
• Inadequate training or continuing professional development of QPs
• Delegation of responsibilities without effective oversight

Such gaps increase the risk of non-compliant products reaching the market.

How to Prevent and Mitigate GMP Failures

To strengthen the QP function and ensure compliance, companies should:

• Establish SOPs defining QP responsibilities for batch review, certification, and oversight
• Ensure QPs have access to all manufacturing, testing, and supply chain data
• Provide regular training on updates to EU GMP guidelines and Annex 16
• Limit batch certification workload to ensure thorough review
• Integrate QPs into deviation, CAPA, and change control processes
• Strengthen collaboration between QPs and supply chain quality functions

Embedding QPs within the quality culture of the organization ensures effective compliance oversight.

Corrective and Preventive Actions (CAPA)

When deficiencies are identified in QP responsibilities, structured CAPA steps include:

1. Document inspection findings or deviations linked to QP oversight
2. Perform root cause analysis to identify systemic issues
3. Revise SOPs to clarify QP decision-making requirements
4. Retrain QPs and supporting personnel on batch certification processes
5. Implement preventive actions such as periodic QP peer reviews or audits
6. Verify CAPA effectiveness through trending of QP-related compliance metrics
7. Ensure management oversight to sustain QP independence and accountability

CAPA ensures that QP oversight deficiencies are corrected and prevented from recurring.

Checklist for Internal Compliance Readiness

• QP has full access to manufacturing and analytical data for each batch
• Batch certification decisions documented and traceable
• Importation of non-EU products includes QP certification under Annex 16
• Deviation and CAPA systems include QP review
• Supply chain GMP compliance verified for APIs and excipients
• Training records demonstrate QP continuing professional development
• SOPs current and aligned with Annex 16 requirements
• Workload allocation allows thorough QP review of each batch
• Mock inspections include review of QP certification procedures
• Management reviews assess QP oversight effectiveness

This checklist helps organizations maintain strong QP involvement and demonstrate compliance during EMA inspections.

Conclusion: Sustaining Compliance Through Proactive Systems

The Qualified Person is the final gatekeeper of quality in the EU pharmaceutical system, with direct legal accountability for GMP compliance. Failures in QP oversight can result in severe regulatory consequences, including suspension of manufacturing licenses. By empowering QPs with resources, clear procedures, and management support, companies can strengthen their compliance posture, prevent costly findings, and safeguard patient safety. The QP role is not just regulatory—it is fundamental to maintaining the integrity of the entire pharmaceutical supply chain.

Abbreviations

• GMP – Good Manufacturing Practice
• EMA – European Medicines Agency
• FDA – Food and Drug Administration
• WHO – World Health Organization
• PIC/S – Pharmaceutical Inspection Co-operation Scheme
• CAPA – Corrective and Preventive Action
• SOP – Standard Operating Procedure
• QMS – Quality Management System
• QP – Qualified Person
• API – Active Pharmaceutical Ingredient

References

• EU GMP Guidelines (EudraLex Volume 4)
• FDA 21 CFR Part 211
• WHO GMP Guidelines
• PIC/S Publications